INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SEC FORM 4/Grant or awardVerified data
MM

McMurry-Heath Michelle reported BVS

Director · Bioventus Inc. · Bioventus Inc. — Restricted Stock Units

Side
A
Value
—
Shares
25.1K
Price
—
Executed
Jun 3, 2026
Disclosed
Jun 4, 2026
Disclosure timeline1 days from execution to publication · legal deadline 2 business days
Jun 3 executedJun 4, 2026 disclosed

BVS · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
5/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

    No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+4 / 15

    2 prior trades recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · BVS

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    5
    MM
    McMurry-Heath MichelleDirector
    BVSBioventus Inc.
    Option exercise
    M—
    32.3K sh
    Jun 2, 2026Jun 4, 2026
    traded Jun 2, 2026
    +2dSEC FORM 4

    Evidence

    17
    MM
    McMurry-Heath MichelleDirector
    BVSBioventus Inc.
    Option exercise
    M—
    32.3K sh
    Jun 2, 2026Jun 4, 2026
    traded Jun 2, 2026
    +2dSEC FORM 4

    Evidence

    9
    DA
    D'Adamio AnthonySVP & General Counsel
    BVSBioventus Inc.
    Option exercise
    M—
    9,925 sh
    Apr 10, 2026Apr 14, 2026
    traded Apr 10, 2026
    +4dSEC FORM 4

    Evidence

    9
    DA
    D'Adamio AnthonySVP & General Counsel
    BVSBioventus Inc.
    Tax withholding
    F$39K
    4,312 sh
    Apr 10, 2026Apr 14, 2026
    traded Apr 10, 2026
    +4dSEC FORM 4

    Evidence

    13
    DA
    D'Adamio AnthonySVP & General Counsel
    BVSBioventus Inc.
    Option exercise
    M—
    9,925 sh
    Apr 10, 2026Apr 14, 2026
    traded Apr 10, 2026
    +4dSEC FORM 4

    Evidence

    9
    SL
    Singleton Mark LeonardSVP & CFO
    BVSBioventus Inc.
    Option exercise
    M—
    13.0K sh
    Apr 10, 2026Apr 14, 2026
    traded Apr 10, 2026
    +4dSEC FORM 4

    Evidence

    12
    SL
    Singleton Mark LeonardSVP & CFO
    BVSBioventus Inc.
    Tax withholding
    F$51K
    5,648 sh
    Apr 10, 2026Apr 14, 2026
    traded Apr 10, 2026
    +4dSEC FORM 4

    Evidence

    13
    SL
    Singleton Mark LeonardSVP & CFO
    BVSBioventus Inc.
    Option exercise
    M—
    13.0K sh
    Apr 10, 2026Apr 14, 2026
    traded Apr 10, 2026
    +4dSEC FORM 4

    Evidence

    13
    SL
    Singleton Mark LeonardSVP & CFO
    BVSBioventus Inc.
    Option exercise
    M—
    18.6K sh
    Mar 20, 2026Mar 24, 2026
    traded Mar 20, 2026
    +4dSEC FORM 4

    Evidence

    12
    SL
    Singleton Mark LeonardSVP & CFO
    BVSBioventus Inc.
    Tax withholding
    F$70K
    8,091 sh
    Mar 20, 2026Mar 24, 2026
    traded Mar 20, 2026
    +4dSEC FORM 4

    Evidence

    9
    SL
    Singleton Mark LeonardSVP & CFO
    BVSBioventus Inc.
    Option exercise
    M—
    18.6K sh
    Mar 20, 2026Mar 24, 2026
    traded Mar 20, 2026
    +4dSEC FORM 4

    Evidence

    17
    CE
    Claypoole Robert EDirector, President and CEO
    BVSBioventus Inc.
    Option exercise
    M—
    33.5K sh
    Mar 13, 2026Mar 17, 2026
    traded Mar 13, 2026
    +4dSEC FORM 4

    Evidence

    9
    CE
    Claypoole Robert EDirector, President and CEO
    BVSBioventus Inc.
    Grant or award
    A—
    278.0K sh
    Mar 13, 2026Mar 17, 2026
    traded Mar 13, 2026
    +4dSEC FORM 4

    Evidence

    21
    CE
    Claypoole Robert EDirector, President and CEO
    BVSBioventus Inc.
    Option exercise
    M—
    33.5K sh
    Mar 13, 2026Mar 17, 2026
    traded Mar 13, 2026
    +4dSEC FORM 4

    Evidence

    9
    CE
    Claypoole Robert EDirector, President and CEO
    BVSBioventus Inc.
    Grant or award
    A—
    309.0K sh
    Mar 13, 2026Mar 17, 2026
    traded Mar 13, 2026
    +4dSEC FORM 4

    Evidence

    24
    CE
    Claypoole Robert EDirector, President and CEO
    BVSBioventus Inc.
    Grant or award
    A—
    153.0K sh
    Mar 14, 2025Mar 17, 2026
    traded Mar 14, 2025
    +368dSEC FORM 4

    Evidence

    16
    CE
    Claypoole Robert EDirector, President and CEO
    BVSBioventus Inc.
    Tax withholding
    F$125K
    14.6K sh
    Mar 13, 2026Mar 17, 2026
    traded Mar 13, 2026
    +4dSEC FORM 4

    Evidence

    24
    CE
    Claypoole Robert EDirector, President and CEO
    BVSBioventus Inc.
    Grant or award
    A—
    134.0K sh
    Mar 14, 2025Mar 17, 2026
    traded Mar 14, 2025
    +368dSEC FORM 4

    Evidence

    28
    MM
    McMurry-Heath MichelleDirector
    BVSBioventus Inc.
    Open-market sale
    SELL$105K
    12.0K sh
    Mar 11, 2026Mar 13, 2026
    traded Mar 11, 2026
    +2dSEC FORM 4

    Evidence

    21
    CE
    Claypoole Robert EDirector, President and CEO
    BVSBioventus Inc.
    Option exercise
    M—
    93.8K sh
    Jan 9, 2026Jan 13, 2026
    traded Jan 9, 2026
    +4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001904156-26-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jun 3, 2026
    Published
    Jun 4, 2026
    Ingested by INSIDER
    Nov 5, 03:54 UTC
    Last re-read
    Nov 5, 03:54 UTC

    Extracted facts

    Filer
    McMurry-Heath Michelle
    Role
    Director
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Bioventus Inc. — Restricted Stock Units
    Ticker
    BVS
    Shares
    25.1K
    Price per share
    $0
    Execution date (reported)
    Jun 3, 2026
    Owned after transaction
    25.1K shares
    Days from execution to publication
    1

    What this establishes

    McMurry-Heath Michelle filed this Form 4 reporting a grant or award of BVS on Jun 3, 2026. It became public on Jun 4, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    McMurry-Heath Michellecik:0001904156
    Issuer
    Bioventus Inc.cik:0001665988

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.